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The extremely poor outcome from pancreas cancer is well known. However, its aetiology less well appreciated, and the molecular
mechanisms underlying this are poorly understood. Tobacco usage is one of the strongest risk factors for this disease, and this is
a completely avoidable hazard. In addition, there are well described hereditary diseases which predispose, and familial pancreas
cancer. We have sought here to summarise the role of tobacco-derived carcinogens and the mode of their tumorigenic action on the
pancreas. There is compelling evidence from animal and human studies (laboratory including cell line studies and epidemiologic)
that tobacco derived carcinogens cause pancreas cancer. However, the manner in which they do so is not entirely apparent. There
is also compelling evidence that synergism with genetic and other life-style factors—like diet obesity—results in a multifactorial
causation of the disease. Ascertaining the role of tobacco carcinogens in the development of this cancer and their interaction with
other risk factors will enable novel therapeutic and preventative strategies to improve outcome from this appalling malignancy.
1. Introduction
Adenocarcinoma of the pancreas is a devastating dis-
ease, and only a small proportion of sufferers achieve
an attempt at curative surgical treatment which leads to
a median survival of about 12 months [1]. In spite of
advances in surgical technology, perioperative care, and
adjuvant treatments the improvement in outcome from
this disease has been minimal. Improving survival could
be the result of an understanding of the biology of the
cancer, and its risk factors with a view to detecting it
early—possibly in high-risk individuals with secondary
prevention strategies in selected patients and also devising
novel modes of interfering with its initiation and progres-
sion.
There have been numerous lines of evidence implicating
tobacco smoking as a risk factor for pancreatic cancer and
this has been well recognised in the field of pancreatology.
Realisation of this in the wider healthcare community,
however, had been limited until the publication of the 2004
US Surgeon General’s report on health consequences of
Smoking [2]. Tobacco usage is the single largest preventable
cause of disability disease and death in the developed world
and probably also plays a great role in morbidity and
mortality amongst people within the developing world.
A recent meta-analysis [3] demonstrated the signifi-
cant strength of the association between cigarette smoking
and pancreas cancer and calculated that the population
attributable risk secondary to tobacco use for the malignancy
was about 20%. Genetic factors play a role in about 10%
of incident cases. However, the exact etiological cause for
the vast majority of these cancers continues to remain
speculative.
Tobacco smoking is the strongest risk factor for pancreas
cancer, but the mechanism of disease causation has not
been elucidated although the various steps in the sequence
of development of the malignancy have been described—
beginning from PAN-IN 1 to invasive adenocarcinoma [4].
On a background of this recent meta-analysis summarising
the evidence linking tobacco use with pancreatic cancer,
we have reviewed the available laboratory and experimental
data, providing a summary of the current knowledge of
tobacco-driven pancreas carcinogenesis.
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2. Search Methods
Established medical databases including PUBMED, MED-
LINE, SCOPUS, and INDEX MEDICUS were searched for
a variety of different combination of the terms pancreas,
pancreatic, cancer, adenocarcinoma, tobacco, use, smoking, and
carcinogens to identify peer-reviewed publications exploring
the relationship between tobacco smoking and pancreas
cancer. After excluding duplicate results, a total of 235
publications were initially identified. They were subjected to
careful scrutiny and we excluded case-control, cohort studies
and other cross-sectional/longitudinal studies published up
until 2008. This was due to an excellent and comprehensive
meta-analysis summarising the epidemiology of tobacco
use and pancreas cancer (vide supra) published in 2008.
All publications dedicated to laboratory, experimental and
clinical consequences of tobacco carcinogen effect on the
pancreas or development of pancreas cancer were identified
and the full-text was carefully scrutinised. We also examined
epidemiological papers published after 2008. Thus for the
purposes of this paper 115 publications were reviewed in
detail.
3. Review
Nicotine is the major psychoactive substance in tobacco
and is responsible for tobacco dependence and addiction.
It is thought to induce a euphoric state in users by the
activation of the mesolimbic dopaminergic reward system
in the nucleus accumbens of the brain [5], and this may be
related to the highly addictive properties of the drug [6].
Individuals have genetically based differences in their
ability to metabolize nicotine as well as genetic differences
in the psychological reward pathways that may influence
individual response to smoking initiation, dependence,
addiction and cessation. While nicotine itself has some
cancer-promoting abilities which we will discuss later, most
of the health consequences of tobacco use are secondary to
the other chemicals within it. Some are nicotine metabolites,
whilst the others are unrelated.
3.1. Tobacco-Derived Carcinogens. Tobacco smoke contains
4000 compounds and 50 carcinogens as compared to 3000
compounds and 30 carcinogens in processed unburnt
tobacco [7]. Both mainstream and sidestream smoke are
harmful and have differing proportions of carcinogens.
These carcinogens include polynuclear aromatic hydrocar-
bons (PAH), tobacco-specific nitrosamines (TSNA),
aromatic amines, aza-arenes, and aldehydes, other organic
compounds like benzene, inorganic compounds like hydra-
zine, and various metals [8] (reviewed by Hecht and
Hoffmann). Seven compounds have been identified in the
family of TSNA’s—NNN (N ′-nitrosonornicotine), NNK
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone), NNAL
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), NAT
(N ′-nitrosoanatabine), NAB (N ′-nitrosoanabasine), iso-
NNAL [iso 4-(methylnitrosamino)-4-(3-pyridyl)-1-buta-
nol] and iso-NNAC [iso 4-(N-methylnitrosamino)-4-(3-
pyridyl)butyric acid)]. NNN, NNK, and NNAL are the most
powerful carcinogens. Nitrosation of nicotine during
tobacco processing and cigarette smoking leads to the
formation of tobacco-specific nitrosamines, of which 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
[9] is the most notorious and is now classified by the
International Agency for Research on Cancer as a Group 1
carcinogen. In the context of pancreatic cancer TSNAs, NNK
and NNAL are particularly important, as they demonstrate
organ specificity towards the pancreas. They are present in
large quantities in both burnt and unburnt tobacco.
TSNAs are procarcinogens. Following exposure, they
need to undergo a series of steps uptake, metabolic activa-
tion, and DNA and protein adduct formation which subse-
quently leads to altered growth kinetics in the target organ
and development of neoplasia. These metabolic pathways of
NNK and NNN have been demonstrated in vivo in mice [10],
rats, and hamsters [11] and in subcellular fractions, cultured
cells and tissues from animals [12] and humans [13].
NNK can undergo hydroxylation, oxidation and carbonyl
reduction to yield numerous metabolites which include
diazoxides, formaldehyde, NNK-N-oxide, and NNAL. These
metabolites react with DNA and protein resulting in adducts
formation. In mice and rats, NNK-derived electrophiles react
with nucleophilic centers in DNA to yield a variety of prod-
ucts including 06-methylguanine which causes miscoding
of DNA during replication [14]. This production of 06-
methylguanine and 06-ethylguanine had also been confirmed
histochemically in pancreatic duct cells in vitro [15].
Until recently, nicotine had been considered to be
responsible for only the addictive property of tobacco only;
however, of late it is being increasingly recognised that
nicotine might independently possess cancer facilitating
properties causing the metastasis of tumours preinitiated by
tobacco carcinogens [16] in rat models of lung cancer. This
effect is thought to be mediated through nicotine stimu-
lation of nAChR (nicotinic acid acetyl choline receptors).
Nicotine can also induce epithelial-mesenchymal transition
in cultured lung, breast and pancreatic cancer cells [17].
This is an essential part of the invasion—metastasis sequence
and therefore it appears that while nicotine has only limited
capacity to initiate tumour formation, it can induce invasion
and metastasis in preexistent tumours.
3.2. Tobacco-Derived Carcinogens and Pancreatic Tumours
in Animals. Numerous animal models of pancreas ductal
cancer have been developed, and these have proved invalu-
able in elucidating the kinetics of the carcinogen within
physiological systems and pathogenesis of ductal cancer
of the pancreas. In 1988, the important role of tobacco
derived carcinogens in extrapulmonary cancers including
the pancreas was highlighted in a commentary by Hecht
and Hoffmann. The same commentary also concluded that
two of the nicotine-derived nitrosamines, NNK and NNN,
are strong carcinogens in laboratory animals and that they
could induce tumors both locally and systemically. Also, the
magnitude to the total doses of NNK and NNN required
to produce cancer in laboratory animals is similar to the
total estimated doses which long-term snuff-dippers or heavy
smokers are exposed life time [8].
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In F-344 rats, NNK and NNAL cause development of not
only lung but also pancreatic adenocarcinoma. The doses of
carcinogens to body weight needed to cause these neoplasms
in rats were similar to lifetime exposure of these chemicals in
heavy smokers (40 cigarettes/day). This was the first example
of pancreatic tumour induction by a constituent of tobacco
smoke. NNAL appeared to be the proximate pancreatic
carcinogen of NNK as it induced more tumours than NNK
[18]. They are the only carcinogens to induce pancreatic
adenocarcinoma in animal models when given systemically
[18, 19]. Also, in F-344 rats, there is evidence that following
oral NNK administration, there is preferential metabolism
of NNK to (S)-NNAL followed by its extensive retention in
various target tissues including the pancreas of NNK-orally
treated animals [20]. Treatment of rats with TSNA’s also
resulted in the induction of pancreatic acinar cell and ductal
cell neoplasms [21].
In rodents it has been shown that NNK and NNAL are
excreted in the bile in significant concentrations [22]. If
this is true in humans, it may be the route through which
activated carcinogens reach the head of pancreas (carcinogen
containing bile refluxing into the pancreatic duct). This
theory is attractive given that the pancreatic head is the most
frequent site for adenocarcinoma [23–25]. A study in rhesus
monkeys (n = 4), however, found that biliary excretion of
the NNK metabolites was significantly less than predicted
from rat experiments. Very limited experiments have been
performed on this route of TSNA excretion.
3.3. Tobacco Carcinogens in Humans and Their Relevance to
Pancreatic Cancer. Most animal studies have been extrapo-
lated to humans and the assumption is that the metabolism
and physiological distribution kinetics of tobacco derived
carcinogens is similar to that in rats and rodents. However,
there will be differences in the manner in which our species
handles these carcinogens, and a few studies have tried to
elucidate this by various means. Essentially, what has been
achieved is to show that the pancreas is exposed to these
chemicals and that these metabolites bind to pancreatic
ductal cell DNA and result in mutations there and that
various phenotypic changes occur there including cancer.
However the exact mechanism by which these carcinogens
turn a normal ductal cell into a malignant one has not been
described.
TSNA’s (NNK and NNAL) have been detected in the
pancreatic juice of smokers in significantly higher quantities
as compared to nonsmokers confirming that the pancreas
is exposed to these carcinogens [26]. It has been shown
that aromatic amines and nitroaromatic hydrocarbons are
metabolically activated in the human pancreas [27]. This
confirmed that the pancreas is exposed to TSNA’s and that
these carcinogens may play a role in carcinogenesis at this
site [22].
Although a strong correlation had been suggested
between cigarette smoking and pancreatic cancer, studies
on pathological changes in the pancreas of smokers are
infrequent. Tomioka et al. performed a comparative autopsy
study on 73 pancreases obtained by autopsy from 42 heavy
cigarette smokers and 31 nonsmoker patients. Although the
incidence of pancreatic cancer in smokers was higher than in
nonsmokers, the difference was statistically not significant.
Ductal changes, including mucinous or squamous cell
metaplasia and papillary hyperplasia, were found with equal
frequencies in both groups of patients and the authors
concluded that the type and the incidence of these ductal
alterations were not related to smoking but to the age. There
were significant limitations of this autopsy study including
limited number of the sections of the pancreas examined,
as well as exclusion of other important variables, such as
alcohol, diet and diabetes weaken the value of this study
[28]. Another autopsy study obtained purified DNA from
human lung, liver, bladder, pancreas, breast and cervix of
13 men and 6 women and analysed it for DNA adducts
using the nuclease P1 modification of the 32P postlabelling
technique. Relatives were asked to provide information on
smoking history for deceased subjects. All tissues examined
except the breast had detectable adducts. In lung, bladder
and pancreatic tissue a characteristic pattern of adducts
was seen which had previously been reported as typical
of cigarette-smoke-induced damage; diagonal reactive zone
[29]. Smokers and former smokers tended to have higher
adduct levels than nonsmokers in the tissues examined but
this was only significant for the lung. These results confirmed
the finding that cigarette smoking is associated with DNA
damage in the lung and suggested that similar damage may
be related to tobacco-induced neoplasms of other tissues
[30]. TSNA’s adducts have been found in the pancreas and
the levels have correlated with dose and time related to
exposure [31].
3.4. Mechanism of Tobacco-Induced Carcinogenesis in the
Pancreas. Over the past 10–15 years extensive work into the
development of pancreatic cancer has been carried out. A
model of stepwise progression from normal to malignant
cells, and the molecular alterations involved in these has been
described [32].
Very similar to the adenoma-carcinoma sequence in the
colon, there is neoplastic progression in the pancreatic ducts
[33–36]. This progression from a normal pancreatic ductal
cell to an infiltrating carcinoma involves sequential multiple
genetic alterations. The genetic changes include activating
point mutations in K-ras, overexpression of HER-2neu, and
inactivation of p16, p53 DPC4, and BRCA2. A gate-keeper
gene for the initiation of pancreatic neoplasia has not been
indentified and the cause of the ignition of change in a
normal ductal cell towards neoplasia is under investigation.
Several mechanisms have been proposed in regard to
how tobacco smoking might be involved in pancreatic
carcinogenesis such as tobacco-carcinogen-induced adducts
resulting in the mutation of the K-ras oncogene and ini-
tiating tumorigenesis and subsequent promotion occurring
by other factors,. However, this is not yet clear, and other
mechanisms such as the autonomic nervous system and
its various pathways, lipid peroxidation, and synergistic
molecular damage by other environmental, occupational,
and other factors may play an important role.
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3.4.1. K-ras Mutations, DNA Adducts, and Tobacco in the
Initiation of Pancreatic Cancer. K-ras mutations have been
identified in various malignancies, including pancreas can-
cers. A number of animal studies have been performed
examining the hypothesis that tobacco smoking-induced K-
ras mutations and that these were the beginnings of the
malignancy [15, 37, 38]. In one of these models, an in vitro
transformation of immortal hamster pancreatic duct cells
was studied after exposure to NNK for varying lengths of
time. Analysis of pancreatic DNA for K-ras mutation at
codons 12, 13, and 61 showed G–A transition at codon 12
of the K-ras oncogene in tumour cells after 1 and 3 days
of NNK treatment. However, no mutation was detected in
tumour cells developing 5 and 7 days after NNK treatment
[15]. One and 3 day NNK-treated cells were able to grow in
the absence of growth factors and serum immediately after
the treatment. Also, the tumorigenicity of these transformed
cells was determined in nude mice, and the cells treated for
1 and 3 days produced well-differentiated neoplasms, while
those that were treated for longer durations did not. Thus,
it appeared that although K-ras mutation at codon 12 of
pancreatic adenocarcinoma was an early event, it was not
necessarily required for the development and/or progression
of the tumours in nude mice.
Numerous studies have been performed in humans
to ascertain the role of K-ras in pancreas development
with conflicting results. Two key studies reporting on this
issue and had divergent results—Nagata et al. observed
a negative association [39], whilst Hruban et al. found
a positive association [40]. In a population-based case-
control study, where information on smoking and other
life-style factors was obtained at direct patient interview,
no significant association between K-ras mutation and
smoking was identified [41]. A meta-analysis of 8 studies
investigating K-ras mutations in various cancers including
pancreas adenocarcinoma [42], explored the hypothesised
association lifetime history of tobacco consumption. No
significant association between the frequency of K-ras muta-
tions (OR = 1.26; 95% CI = 0.82–1.94) and tobacco usage
was identified. Subsequently, the PANKRAS 2 study group
authors reported a case-case study [43], where they did not
find any association between acquisition of K-ras mutations
and tobacco smoking. In combination, these studies have
contributed to the conclusion that while both smoking
and K-Ras mutations are important in the development of
pancreas cancer, they are independent of one another.
3.4.2. Promotion. Recent studies have demonstrated over-
expression of cyclooxygenase and 5-lipoxygenase receptors in
exocrine pancreatic carcinomas [44]. Following on from this,
Weddle et al. demonstrated high basal levels of arachidonic
acid release and expression of m-RNA for β adrenergic
receptors (1 and 2) in two human cell lines derived from
exocrine ductal pancreatic carcinomas. Notably, exogenous
NNK promoted DNA synthesis in these cells [45]. This
study therefore underlined the importance of β-adrenergic
mechanisms in pancreas carcinogenesis (as had previously
been reported for lung cancer [46, 47].
NNK reportedly binds with high affinity to adrenergic
and nicotinic receptors and activates downstream signalling
pathways, inducing cellular proliferation cancer cell lines
derived from human pancreas, breast and lung malignancies
[48]. In a hamster model of exocrine pancreatic cancer
induced by transplacental exposure to ethanol and the
tobacco-carcinogen NNK [49], Schuller et al. reported
a reduction in the development of pancreatic cancer in
offspring who had been given the arachidonic acid pathway
inhibitors, ibuprofen or MK886. Tumour development was
reduced by 50% or 30%, respectively [49]. The reduction
was not a result of an interaction with the drugs on NNK
metabolism or cancer initiation events, as the NNK was
administered as a single dose on day 15 of gestation, while
the preventive treatments started 4 weeks later, when the
offspring were weaned from their mothers. Of note, no
mutations in the Ki-, N-, or H-ras or p53 genes were found
in theses tumours.
There is also recent evidence indicating that NNK is an
agonist for nicotinic acetylcholine receptors (nAChRs), and
in hamsters, NNK-induced alterations in regulatory nAChRs
may contribute to the development of smoking-associated
PAC and PDAC by disturbing the balance between cancer-
stimulating and inhibiting neurotransmitters [50].
In combination, these findings suggest that NNK is a β-
adrenergic agonist. β-adrenergic, AA-dependent regulatory
pathways in pancreatic cancer are a possible novel target-
dietary or pharmacologic for cancer intervention strategies
[51] in an effort towards the prevention and clinical man-
agement of pancreatic cancer.
3.5. Synergistic Cofactors Contributing to Tobacco Related
Pancreatic Carcinogenesis? While we are beginning to under-
stand some of the key factors involved in pancreatic carcino-
genesis, of which smoking is one, the primary etiology of the
disease remains poorly understood. Other epidemiological
factors may also be important and a genetic predisposition to
the disease, supported by reported familial occurrences of the
disease [52–54] has long been suspected. As reviewed here,
investigators have struggled to show that tobacco contributes
directly to the development of acquired mutations in the
commonly reported oncogenes and tumour suppressor
genes. However, there may well be a more subtle association,
with innate or inherited genetic variation, which increases
an individuals exposure to damaging agents, or possibly that
individuals ability to repair induced DNA damage. There
may also be interplay here, as with all polygenic diseases, with
other environmental factors.
Certainly, there is a lot of individual variation in the
metabolism of the known tobacco-derived carcinogens.
Metabolically activated NNN and NNK bind not only to
DNA but also to the protein moiety of haemoglobin resulting
in globin-carcinogen adducts. Mass-spectroscopic studies
have detected a significant overlap of the globin-carcinogen
adduct levels between smokers and nonsmokers, suggesting
that individuals vary in their ability to activate TSNAs [55].
As previously mentioned, there is also considerable variation
in adduct levels in the pancreas at autopsy among smokers,
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which could not be accounted for by duration or daily
consumption level [30]. While the evidence for a synergistic
role between smoking and other factors is limited, the key
suspects are mentioned here.
(a) Dietary Factors. Various groups of researchers have
explored the interaction of tobacco smoke with dietary and
other factors in animal models in an attempt to replicate the
scenarios found in humans, and there is evidence that some
dietary factors act synergistically with these carcinogens.
Coadministration of sinigrin (a glucoside found in some
plants of the Brassica family such as brussels sprouts, broc-
coli, and seeds of black mustard) with NNK, for example,
resulted in a significant incidence of pancreatic tumors in
rats [56]. In a long-term bioassay (24 months) exploring
the interaction of dietary fat and tobacco carcinogens, F344
rats were given NNK, in the drinking water. In addition, one
group of rats was given a high-corn oil diet and the second
group received a low-corn oil diet. There were control groups
with similar diet and on plain tap water only. The NNK +
high corn oil group gained more weight and developed more
number of pancreas tumours as compared to the NNK + low
corn oil group. There was no such effect on development
of lung cancers in the animals. This elegant and simple
bioassay provided supplementary evidence to corroborate
epidemiological studies which had suggested a link between
daily fat intake and pancreas cancers in smokers [57].
(b) Obesity. Obesity is now recognised as a risk factor in
development of all cancers, but this is particularly so for
pancreatic cancer. Wang et al. reported a 2.6 fold increase
in relative risk of a pancreatic cancer associated death in
individuals with a body mass index greater than or equal to
35. The animal study above, in which the fatter NNK group
fed corn oil developed more pancreatic cancers, supports this
although the actual cause is as yet unclear. A further study
demonstrated that body mass index was positively correlated
to the levels of DNA, lipid peroxidation related adducts
and the total aromatic adducts in pancreatic tumour tissues
[58]. These observations support the hypothesis that DNA
damage related to a combination of carcinogen exposure
and lipid peroxidation may be involved in human pancreatic
carcinogenesis.
(c) Alcohol. A key dietary factor worthy of independent
mention is alcohol. Alcohol has long been suspected of
contributing to pancreatic cancer development [59, 60],
but a synergistic role with tobacco exposure has also been
considered. In pregnant animal models, NNK can cross the
placenta following tracheal administration and cause its car-
cinogenic effect-pancreas cancer on the foetus. Concomitant
administration of ethanol can greatly potentiated this effect
[61], but other than recommending that pregnant women
neither drink nor smoke, the human relevance of these
findings is unclear. The PANKRAS 1 study investigated the
presence of K-Ras mutations in patients who either smoked,
or drank alcohol, or did both. The information in this study
was taken from patient notes rather than a questionnaire,
but reported a higher risk only in those who did one or
the other, rather than both [62]. As discussed previously,
the frequency of K-Ras mutations is probably not the best
tool to assess the impact of suspected carcinogens, and the
true impact of smoking in combination with alcohol on
pancreatic carcinogenesis has yet to be determined.
(d) Genetic Factors. A genetic predisposition is frequently
alluded to in reviews of the aetiology of pancreatic cancers
[63, 64] and certainly there are genetic disorders, such
as Hereditary pancreatitis [65, 66], the Liefraumeni syn-
drome [67], Peutz-Jeghers syndrome [68] and Hereditary
nonpolyposis colon cancer syndrome [69]. Familial atypical
melanoma mole syndrome [70] where pancreatic cancer is
a major feature. Furthermore, familial pancreatic cancer is a
well recognised entity [71–73]. A recent retrospective cross-
sectional cases-only study suggested an increased risk for
pancreas cancer when multiple environmental risk factors
(including tobacco smoke exposure) were present on a
background of a family history of pancreas cancer [74]. This
study has again emphasised the role of environmental factors
in modulating the genetic risk for development of pancreas
cancer.
When considering potential synergy between innate sus-
ceptibility and tobacco derived carcinogens, we are beginning
to look toward genetic variability in the ways in which
tobacco derived compounds or metabolites interact with
targets, are metabolised, or even the ways in which the
damage incurred is repaired. Polymorphisms in genes coding
for dopamine receptors and transporters, nicotinic receptors
and serotonin receptors, neurotransmitters and transporters
[75] may be relevant, and certainly understanding the
genetic factors involved in addiction may ultimately result
in more effective tobacco cessation programs reducing the
incidence of tobacco related diseases, including pancreatic
cancer. In addition, however, we are beginning to understand
individual variability of susceptibility to damage at a more
molecular level.
Both the quantity and duration of exposure to car-
cinogens may determine adduct formation or the capacity
to cause damage. The carcinogens themselves may be
metabolised at different rates in individuals. In human pan-
creatic tissues, there is individual variability in the capacity
for, and stereoselectivity of, carbonyl reduction of NNK. In
individuals whose microsomes metabolize NNK at a lower
rate but form predominantly (S)-NNAL, “stereoselective
localization of (S)-NNAL” in the human pancreas might
occur, similar to the rat lung, where S-NNAL gets retained
resulting in higher incidence of cancers there [76].
One family of proteins with an important role in the
metabolism of foreign compounds and drugs, and, therefore,
a key suspect in promoting cancer predisposition if relatively
ineffective in some circumstances, are the cytochrome P450
(CYP) superfamily. There is a vast literature reporting var-
ious genetic polymorphism in CYPs which increase cancer
susceptibility. As yet, this is largely unconfirmed, with the
exception of CYP2A6 polymorphism and tobacco-induced
cancer [77, 78]. The role of these in tobacco related cancer
has been summarised by others [78–80] and is not discussed
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in depth here. In summary, although they have significant
effects on tobacco-derived carcinogen metabolism, they are
not considered to play an important role in pancreas cancer
causation. Phase-2 metabolising enzymes such as Uridine-
diphospho-glucuronosyl transferase (UDPGT) [81], Glu-
tathione S-transferase (GST) [82–85] have also been studied
but are reported from relatively small single institution
studies and need validation in large case-control molecular
epidemiological studies.
As well as variability in the capacity to cause damage,
those pathways involved in the repair of damage have been
studied, with significant individual variation reported. In
particular, the role of polymorphisms of genes coding for
enzymes and proteins within key metabolic and DNA repair
pathways in modulating risk for human pancreas cancer is
being investigated and has been the subject of recent reviews
[86–88]. Numerous small single centre studies exploring the
role of gene-environment interaction and interindividual
variability in susceptibility to tobacco derived carcinogen
damage [77, 89–95] have recently been reported and require
validation. In addition, genome wide association studies
(GWAS) in large numbers of individuals with pancreatic
cancer are being performed and may ultimately lead us
closer to the key genetic factors involved. The first of
these confirmed an earlier epidemiologic finding that blood
group O results in a decreased risk for pancreas cancer
[96]. Another GWAS in Japanese individuals, who have a
particularly high risk of pancreatic cancer, was reported
in 2010 and identified genes on chromosomes on 6, 7,
and 12 [97] and A further similar but larger study has
suggested other specific loci on chromosomes 1, 5, and 13
to be associated with an increased risk for the malignancy;
however, the functional significance of these findings is not
clear.
4. Conclusion
Tobacco, as it is used in its most prevalent form, that
is, smoking, is the most important risk factor for the
development of pancreas cancer. There is compelling epi-
demiological evidence for a disease-causation effect for this
which is backed up by physiological evidence based on
laboratory studies on subcellular fractions, cell lines derived
from human and animal models of the disease, whole animal
models and human studies. There is also significant evidence
for interindividual variation in susceptibility to tobacco-
derived carcinogens which is a field of intense current
research. Understanding of the role of not only tobacco
carcinogens, but also the possible toxic role of nicotine itself
in humans needs to be emphasised in public awareness
campaigns.
Further work is urgently required to explore the complex
interactions between genetic, life-style/environmental fac-
tors at both laboratory and population levels to understand
the disease better and enable improvement in outcome by
not only earlier diagnosis, but also innovative and newer
modes of intervention.
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